DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for metabolic syndrome — screening already-approved drugs against its 53-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMetabolic syndrome maps to a 53-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedMelatoninMelatonin receptor agonist
Structures already discussed alongside metabolic syndrome in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of fad quinone reductase 2 — Melatonin has a real, experimentally solved structure in complex with this target (PDB 4QOG, 1.4 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet ml1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4QOG · 1.4 Å · ligand Melatonin (ML1). Experimental structure, not a prediction.
What the evidence adds up to
Metabolic syndrome is defined as a cluster of cardiometabolic risk factors — obesity, diabetes, dyslipidaemia, and hypertension — that synergistically increase the risk of heart disease and stroke. The syndrome is understood to arise from an evolutionary mismatch: the human body, unprepared for dietary excess of nutrients (especially lipids), responds with metabolic signals similar to starvation, limiting glucose use and amino acid oxidation. The immune system and hypertrophied tissues mount a defence response that is probably the ultimate basis of the disease. Multiple genes and pathways play important roles in its development, and the molecular mechanisms involve insulin resistance, inflammatory processes, and hereditary predispositions.
No highly effective pharmacological agent for metabolic syndrome as a single entity has yet been developed. Current treatment strategy focuses on treating its individual components with anti-hypertensive, anti-diabetic, and anti-lipidemic agents. Various medical treatments have been tried but have not been very effective. Modifications in lifestyle — increasing exercise, weight reduction, and diet — are recommended, and pharmacological treatment should be considered when necessary based on the best available evidence. The most effective way to control weight is still surgery, defined as surgical interventions to treat metabolic syndrome.
Promising molecular targets have emerged from animal models, and modulating these targets is expected to treat at least some components of metabolic syndrome. A few promising drug discovery efforts have been reviewed, encompassing central nervous system and peripheral targets. New regulatory guidelines need to be developed as new treatment options are being investigated. The prevalence of metabolic syndrome is rising worldwide due to increasing obesity and sedentary lifestyles, affecting both children and adults.
What is still missing is a single highly effective agent that treats the syndrome as a whole rather than its separate components. The molecular pathways are complicated, multidimensional, and sophisticated, and no prognostic or diagnostic tools have been developed from them. Clinical trials that test a unified treatment against the full cluster of risk factors, rather than each element in isolation, have not been reported. Patient stratification by genetic or environmental factors remains unexplored in treatment studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Diabetes Metabolic Syndrome and Obesity · 2018 · 29 citations · open access
Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
AbstractBACKGROUND: Follistatin (Fst) promotes brown adipocyte characteristics in adipose tissues. METHODS: Abdominal fat volume (CT scan), glucose clearance (GTT test), and metabolomics analysis (mass spectrometry) of adipose tissues from Fst transgenic (Fst-Tg) and wild type (WT) control mice were analyzed. Oxygen consumption (Seahorse Analyzer) and lipidomics (gas chromatography) was analyzed in 3T3-L1 cells. RESULTS: Fst-Tg mice show significant decrease in abdominal fat content, increased glucose clearance, improved plasma lipid profiles and significant changes in several conventional metabolites compared to the WT mice. Furthermore, overexpression of Fst in 3T3-L1 cells resulted in up regulation of key brown/beige markers and changes in lipidomics profiles. CONCLUSION: Fst modulates key factors involved in promoting metabolic syndrome and could be used for therapeutic intervention.
The role of melatonin supplement in metabolic syndrome
AbstractPurpose Metabolic syndrome contains metabolic disorders that have association with other chronic diseases. Melatonin is a bioactive compound which is found in plants and also produced in the body. The purpose of this paper is to assess the effect of melatonin supplement on metabolic syndrome components, also leptin and adiponectin blood concentrations in patients with metabolic syndrome. Design/methodology/approach A double blind, placebo-controlled, randomized clinical trial was conducted on 70 subjects with metabolic syndrome. Participants received 6 mg/day melatonin or placebo before bedtime for 12 weeks. At the beginning and end of treatment period, blood samples were collected and biochemical parameters were measured. In addition, blood pressure and anthropometric indices were examined before and after the supplementation. Independent sample t -test was used to compare changes in metabolic syndrome components between the two study groups. Findings Results showed a significant reduction in waist circumference (−1.54 vs −0.04 cm; p = 0.036), systolic blood pressure (−3.52 vs 0.79 mmHg; p = 0.020), diastolic blood pressure (−1.50 vs 1.73 mmHg; p = 0.014), serum leptin concentration (−2.54 vs 0.27ng/ml; p = 0.041) and an elevation in high-density lipoprotein cholesterol (2.19 vs −0.79 mg/dl; p = 0.038) in the melatonin group compared to the placebo. Research limitations/implications If insulin concentration had been measured, it might have revealed better interpretation of melatonin effect on fasting blood glucose. Originality/value This study showed that melatonin as a nutritional supplement improved most metabolic syndrome components and concentration of leptin in the melatonin group compared to the placebo.
Journal of Endocrinology and Metabolism · 2012 · 8 citations · open access
Metabolic Syndrome: A Multifaceted Disease of Affluence
AbstractMetabolic syndrome developed in consequence of an evolutionary inadequacy: the human body was unprepared for a dietary excess of nutrients, especially lipids (largely in detriment of carbohydrate). This excess awakens metabolic signals akin to those of starvation, in which the main energy staple is the body’s own lipid reserve. Lipid dietary abundance prevents the use of glucose, which in turn limits the oxidation of amino acids. To ward against a subsequent avalanche of substrates, the immune system and hypertrophied tissues ( for example, adipose) elicit a series of defence responses. This response is probably the ultimate basis of a disease that is manifested as various pathologies, which were initially defined as distinct entities but which are slowly being seen as a single pathognomic unit in the literature. Based on their common origin of the ample availability of food in our modern society, the cluster of diseases comprising the metabolic syndrome is probably best described as a single multifaceted disease. J Endocrinol Metab. 2012;2(4-5):155-165 doi: https://doi.org/10.4021/jem116w
Emerging Therapeutic Targets for Metabolic Syndrome: Lessons from Animal Models
AbstractBACKGROUND: Metabolic syndrome is a cluster of medical conditions that synergistically increase the risk of heart diseases and diabetes. The current treatment strategy for metabolic syndrome focuses on treating its individual components. A highly effective agent for metabolic syndrome has yet to be developed. To develop a target for metabolic syndrome, the mechanism encompassing different organs - nervous system, pancreas, skeletal muscle, liver and adipose tissue - needs to be understood. Many animal models have been developed to understand the pathophysiology of metabolic syndrome. Promising molecular targets have emerged while characterizing these animals. Modulating these targets is expected to treat some components of metabolic syndrome. OBJECTIVE: To discuss the emerging molecular targets in an animal model of metabolic syndrome. METHODS: A literature search was performed for the retrieval of relevant articles. CONCLUSION: Multiple genes/pathways that play important role in the development of Metabolic Syndrome are discussed.
Síndrome metabólico y enfermedad vascular cerebral: evidencias en su tratamiento
AbstractINTRODUCTION: Stroke (cerebrovascular disease) is the leading cause of disability and the third of death worldwide. It is considered an age-related disease, although there are several modifiable risk factors, including the simultaneous and frequent combination of obesity, hypertension, dyslipidaemia and elevated fast glucose, which has been labeled the metabolic syndrome; nowadays, it is associated with generalized and brain atherosclerosis. DEVELOPMENT: It is analyzed here how both different components of metabolic syndrome and metabolic syndrome itself are important risk factors for suffering stroke, one by one and all grouped together as well. Based on the best available clinical evidence, appropriated medical management strategies are proposed (evidence-based treatment). CONCLUSIONS: It is proposed a comprehensive medical treatment approach, targeted on the metabolic syndrome trough simultaneous management of individual components; currently, modifications in lifestyle (increasing exercise, weight reduction and diet) are recommended; besides, based on the best available evidence, pharmacological treatment should be considered when necessary.
Expert Opinion on Investigational Drugs · 2004 · 3 citations
Targeting Metabolic Syndrome
AbstractMetabolic syndrome has been recognised as a cluster of risk factors contributing to the development of cardiovascular diseases. Different diagnostic criteria have been proposed and the consensus focuses on four major risk factors: obesity, diabetes, dyslipidaemia and hypertension. Although treatment options are available to treat each component separately, a highly effective agent for metabolic syndrome has yet to be developed. To explore the clinical definition of metabolic syndrome and potential molecular targets that can be modulated for treatment purpose, a meeting entitled 'Targeting Metabolic Syndrome' was organised in 2004 by IBC USA Conferences, Inc. This article highlights discussions related to the clinical correlates and pathophysiology of metabolic syndrome, and reviews some of the promising drug discovery efforts. Metabolic syndrome should be treatable and preventable if obesity and insulin resistance are well controlled. New regulatory guidelines need to be developed as new treatment options are being investigated. From a broad spectrum of potential mechanisms encompassing central nervous system targets and peripheral targets for pharmacological intervention, a few promising molecular targets have emerged. Modulating these is expected to treat at least some components of metabolic syndrome.
Kafkas Journal of Medical Sciences · 2021 · 0 citations · open access
What is Metabolic Surgery? To Whom and When Should It Be Applied?
AbstractMetabolic syndrome is a cluster of cardiometabolic risk factors that cause some complications. Each component of the syndrome needs to be treated. For this purpose, anti-hypertensive, anti-diabetic, and anti-lipidemic agents are used, but weight control plays a key role in treatment. Exercise, reduction of daily calories with diet and increasing physical activity play a role in the control of body weight. Various medical treatments have been tried, but they have not been very effective. The most effective way is still surgery. Although there is no definite accepted definition of metabolic surgery, it can be defined as surgical interventions to treat metabolic syndrome.
AbstractMetabolic syndrome (MetS) has become a worldwide health problem, affecting children and adults globally. The prevalence of MetS is rising all over the world due to increasing obesity and sedentary lifestyles. MetS is caused by the interaction of both genetic and environmental factors.MetS is characterized by complicated, multidimensional, and sophisticated molecular pathways that involve insulin resistance, inflammatory processes, and hereditary predispositions. Here we are trying to focus on common molecular mechanisms that underlie MetS occurrence, aiming to offer a better understanding of their role in MetS and helping in developing prognostic/diagnostic tools and targeting novel therapeutic options.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
